![Ola Camber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ola Camber
Amministratore Delegato presso Camber Consulting AB
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Erik Bissessar | M | - |
Eribis Pharmaceuticals AB
![]() Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | 18 anni |
Herman Krapf | M | - |
Eribis Pharmaceuticals AB
![]() Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | 18 anni |
Jan-Eric Sundgren | M | 73 |
Vetenskapsrådet
| - |
Anders Olof Adolf Ekblom | M | 70 |
Vetenskapsrådet
| - |
Jan Nilsson | M | 71 |
Vetenskapsrådet
| - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Svezia | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ola Camber
- Contatti personali